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ABSTRACT 
International Journal of Exercise Science 14(2): 1018-1026, 2021. Hypertrophic cardiomyopathy (HCM) 
is an autosomal dominant disease that causes myocardial remodeling. Physical exercise (PE) is a therapeutic 
resource used in Supervised Cardiac Rehabilitation (SCR) to improve Quality of Life (QL), reducing cardiovascular 
morbidity and mortality. Therefore, the aim of this study is to report how SCR using a personalized exercise 
prescription, promoted Reverse Myocardial Remodeling (RMR), improved functionality and QL of a patient with 
HCM. This is a case report of a 43-year-old sedentary female patient with a Body Mass Index (BMI) of 24.7 kg/m2. 
The patient was diagnosed with Septal Type Asymmetric HCM. Heart Failure (HF) grade III / IV, according to the 
New York Heart Association (NYHA), was initially treated with 40mg of Propranolol Hydrochloride twice a day, 
and presented with excessive fatigue, and angina. The echocardiogram showed a final diastolic volume (FDV) of 
130 ml, a final systolic volume (FSV) of 44 ml, a left ventricular mass (LVM) of 236 g, interventricular septum 
thickness of 14 mm, left ventricular posterior wall (LVPW) thickness of 9 mm, left atrium diameter 46 mm, left 
ventricular end diastolic diameter of 52mm, septum/left ventricular wall ratio of 1.55 mm, and ejection fraction 
(EF) of 66% (Teicholz). It was obtained as a result of decreased FDV 130 vs. 102ml, decreased FSV 44 vs. 32 ml, 
decreased LVM 236 vs. 201 g, increased EF 66 vs. 69%, 26% improvement in QL, and 50% reduction in the dosage 
of Propranolol Hydrochloride. These results suggest that a personalized SCR program is an adjuvant treatment 
capable of promoting RMR and improving QL and functionality in a patient with HCM. 
 




Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disease that causes myocardial 
remodeling (concentric hypertrophy) (8). It expresses an intracellular anomaly, affecting the 
spatial organization of myofilaments, and favors the development of arrhythmias, such as 
supraventricular and non-sustained ventricular tachycardia/or sustained, which confers an 
increased risk of sudden death (3, 8). 
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HCM presents with diastolic ventricular dysfunction, preservation of systolic function, and 
normal ejection fraction (EF), assessed by Echocardiogram (ECO) (3). Clinically, a decrease in 
functional capacity is observed, which directly compromises the activities of daily living (ADL) 
leading the individual to a progressive decline in quality of life (QL) (12). Physical exercise (PE) 
is able to promote reverse myocardial remodeling (RMR) in hearts with concentric hypertrophy 
and/or dilatation, as well as being a therapeutic resource used in Cardiac Rehabilitation (CR) to 
improve QL and reducing cardiovascular morbidity and mortality (13). 
 
Studies on PE in HCM showed improvement in functional capacity and QL, however, they did 
not investigate RMR (4, 11). Thus, this study aims to report as a Supervised Cardiac 
Rehabilitation (SCR) work, using a prescription of personalized exercise, promoted RMR, 





This is a case report of a sedentary female patient, 43 years of age, and a Body Mass Index (BMI) 
24.7 kg/m2. At 16 years old, she was diagnosed with hypertrophic asymmetric cardiomyopathy 
of septal predominance, through screening tests (electrocardiogram and ECO). These tests were 
repeated annually, due to the genetic load of maternal origin. However, the symptoms did not 
appear until the age of 16, accentuating at the age of 17. Since then, annual examinations have 
been carried out in conjunction with family research, in which a genetic load of maternal origin 
has been discovered. As of 2010, the ECO was always performed with the same 
echocardiographer. 
 
The patient was referred to the Cardiovascular Rehabilitation service at the Clinical School of 
the Adventist College of Bahia, Cachoeira, Brazil (BA), in February 2019. For the treatment of 
heart failure (HF) due to HCM, she used propranolol hydrochloride (40 mg) twice a day. She 
presented with cardiovascular complications; among them, a picture of non-sustained 
ventricular and supraventricular tachycardia determined through the 24-hour ECG-Holter 
exam, HF grade III/IV according to the New York Heart Association (NYHA), excessive fatigue, 
and angina on habitual efforts. 
 
During the physical therapy evaluation, the patient answered the Minnesota Living with Heart 
Failure Questionnaire (MLHFQ), with a score ranging from zero to 105, obtaining a score of 64. 
She reported discomfort during sleep, a feeling of suffocation (characteristic of paroxysmal 
nocturnal dyspnea), and felt it was necessary to support stand on the pillows at a 45º angle, 
while remaining supine to get to sleep. She also reported great difficulty in performing activities 
of daily living, such as bathing, walking, sweeping the house, hanging clothes, getting dressed, 
going up and down stairs, and picking up objects in high or very low places due to dyspnea 
during small efforts, as well recurrent syncope. 
 
In the Doppler echocardiogram exam performed on April 24, 2018, the following descriptive 
variables were verified: final diastolic volume: 130 ml, final systolic volume: 44 ml, left 
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ventricular mass: 236 g, thickness of interventricular septum: 14 mm, thickness of left ventricular 
posterior wall (LVPW): 9 mm, left atrium diameter: 46 mm, left ventricular end diastolic 
diameter: 52 mm, left ventricular septum/wall ratio: 1.55 mm, and an ejection fraction of 66% 
(Teicholz). The report attested moderate left ventricular diastolic dysfunction (Type II), 
increased left ventricular filling pressure, moderate left atrial dilation (Type II), mild degree 
mitral valve insufficiency, degree aortic valve insufficiency discreet, and concentric left 
ventricular hypertrophy and dilation. 
 
The ECG-Holter, performed on December 4, 2017, demonstrated the presence of ventricular 
arrhythmias (five of which were isolated and one episode in pairs) and  supraventricular 
arrhythmias (115 were isolated, nineteen paired, and three non-sustained tachycardias). 
According to the Brazilian Guidelines for Implantable Electronic Cardiac Devices (7), the 
recommendations for implantation of an implantable cardiodefibrillator in patients with HCM 
are divided into classes: Class I - Patients with HCM who have presented ventricular tachycardia 
Sustained Ventricular Fibrillation of non-reversible cause and expectation life span of at least 
one year, Class II - Patients with HCM who have one or more major risk factors for sudden 
cardiac death and life expectancy of at least one year, Class III - HCM patients without risk 
factors. After the patient underwent an evaluation with the arrhythmologist, she was not 
indicated for the implantation of the implantable cardiodefibrillator. In view of the 
physiotherapeutic evaluation performed and the patient's clinical condition, the objectives of 
the SCR were: Increased functional capacity, improved ADL, without the patient having 
dyspnea or syncope and consequently improving QL.  
 
This case report was approved by the Research Ethics Committee of Adventist College of Bahia, 
Cachoeira, BA, Brazil under CAAE nº 39825620.2.0000.0042, in accordance with the Declaration 
of Helsinki. This research was carried out fully in accordance with the ethical standards of the 
International Journal of Exercise Science (9). 
 
Protocol 
The individualized SCR protocol started on February 12, 2019 and lasted for five months, with 
a frequency of two weekly sessions. The sessions consisted of inspiratory muscle training (IMT), 
neuromuscular exercises, handgrip exercises, and cyclic exercises, performed under 
electrocardiographic monitoring (ECAFIX multi-parameter cardiac monitor, Active® model, 
São Paulo, SP, Brazil). 
 
Initially, two subjective effort perception scales (SEPS) were presented and anchored to 
determine the intensity of the exercises. The Borg scale applied in cyclic exercises and the SEPS 
of Omni used to determine the effort of the active musculature in neuromuscular exercises. In 
the first month, an adaptive training was elaborated, after that period the patient underwent a 
reassessment, and the SCR protocol was updated for a conditioning training (Table 1). It is worth 
noting that Borg was applied in limiting neuromuscular exercises, so that a cardiorespiratory 
effort > 9 was not exceeded in the first month, and > 13 in the following months. However, the 
intensity of neuromuscular exercise was determined by Omni. 
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The IMT load was prescribed according to Oliveira et al. (10), which is based on the glycemic 
threshold through the maximum incremental test of resistance of the inspiratory muscles. The 
resistance of inspiratory muscles was assessed using POWERbreathe® K5, connected to the 
computer using the BreatheLink® software. This test is characterized as non-continuous 
incremental and consists of up to ten stages with an interval of two minutes between them. The 
test starts with 10% of the maximum value, increases 10% at each level, with blood glucose, 
Borg, blood pressure and heart rate collections at the end of each level. As the equipment only 
imposes the load determined on the fourth inspiration, 19 incursions were made at each level, 
with a five-second breathing cycle guided by a beep of the device. The test was interrupted on 
the load in which the volunteer was unable to win it or expressed an inability to continue the 
test, calling this the point of exhaustion. 
 
The glycemic threshold was detected by means of blood collections through puncture in one of 
the digital pulps. After asepsis with alcohol (70%) using lancets and disposable procedure 
gloves, blood glucose values were obtained by applying the blood on a test tape attached to the 
glucose monitor G-TECH free® (expressed in mg/dL) that obtained the results immediately 
after contact with the blood in the lancet. The glycemic threshold was determined by visual 
inspection, as the lowest value of the glycemic curve built in the test. At the point where the 
glycemic threshold was found, the Borg of the obtained load was anchored. This allowed us to 
evolve the load in the other months by adjusting it using the Borg. During the first month, we 
opted for the IMT to be performed during the service session at the school clinic, aiming at 
adapting the patient to the device. Subsequently, the IMT was allowed to be done at home three 
times a week on days when it did not attend the SCR. 
 
To determine the handgrip load, we used the WCT Fitness® HandGrip dynamometer and 
followed the dynamometer protocol of the American Society of Hand Therapists (2). Therefore, 
the patient was positioned in sedestation in a chair with a straight back and without support for 
the arms, with arms adducted and neutrally rotated shoulders, elbow flexed at 90º and forearm 
in neutral position. After being in the oriented position, the patient was asked to squeeze the 
dynamometer as tightly as possible, making three attempts on each hand with a one-minute rest 














Int J Exerc Sci 14(2): 1018-1026, 2021 
International Journal of Exercise Science                                                          http://www.intjexersci.com 
1022 
Table 1. Exercise protocol for February (adaptive training) and March to June (conditioning training). 




3 series of 10 
inspirations  











2 sets of 10 reps  






 Omni from 1 to 3# 
 Borg from 7 to 9* 





 Borg from 7 to 9*,  
reaching an 





5 series at 10% 
of the load 
obtained in 
dynamometry  
2 times weekly 







 Omni from 3 to 5# 





2 sets of 12 reps  
2 times weekly 
- 




 Omni from 3 to 5# 
 Borg from 11 to 13* 
Treadmill 5 sets  2 times weekly 1 minute 




 Borg from 11 to 13* 
 Heating speed on 
average 1.1km/h  
 Conditioning 
speed on average at 
2.0km/h 
¥Elbow flexion, elbow extension, knee flexion and knee extension, *Borg used for the patient to achieve the proposed 
muscle effort, without exceeding a cardiorespiratory effort > 9 in the adaptation training and >13 in the conditioning 




Table 2 represents the comparison of the Doppler echocardiogram variables and the percentage 
of improvement before and after the patient joined an SCR program. It is worth mentioning that 
both exams were performed by the same echocardiographer and the patient’s weight and height, 
respectively, were 72 kg and 167 cm in both exams. 
 
From the results obtained in Table 2, we can highlight a 15% decrease in left ventricular mass, a 
27% decrease in final stroke volume, a 22% decrease in final diastolic volume, and a 4% 
reduction in the diameter of the Left Atrium (LA), which reflects a decrease in dilation and 
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Table 2. Echocardiographic measurements comparing pre and post SCR values. 







Left Atrium diameter (mm) 46 44 40 4% 
Final Diastolic Volume (ml) 130 102 46 - 106 22% 
Final stroke volume (ml) 44 32 14 - 42 27% 
Diastolic thickness of LVPW (mm) 9 9 7 - 10 - 
Diastolic Thickness of the Septum (mm) 14 14 7 - 10 - 
Left Ventricular Mass (g) 236 201 67 - 162 15% 
Mass of the LV/  Body Surface (g/m2) 131 111 43 - 95 15% 
Ejection Fraction (%) # 66 69 54 - 74 5% 
*Reference values of the American Society of Echocardiography and the European Cardiovascular Imaging 
Association (6), #Ejection Fraction (Simpson), LVPW: Left Ventricular Posterior Wall, LV: Left Ventricle.  
 
Figure 1 represents the MLHFQ score (an important tool to assess QL in individuals with HF), 
which was applied before and after the SCR. After the SCR, there was an improvement in the 




Figure 1. Score obtained in the QL test before and after the SCR. 
 
The SCR program also made it possible to reduce the dosage of the drug, propranolol 
hydrochloride, in half. In the last month of SCR, a patient started to show bradycardia and 
hypotension during and after exercise. In the face of these events, the same was referred to the 




The results of this case report suggest that a SCR program is a cost-effective adjunctive treatment 
in HCM, capable of promoting RMR and improving functionality and QL. It is well established 
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in the literature that physical exercise is capable of inducing RMR, both for dilation and 
concentric hypertrophy (5). Although we have not seen regression of concentric hypertrophy, 
we have seen reversal of dilation. This is observed in Table 2, in which there is a substantial 
reduction in the final diastolic and systolic volumes, in the left atrium diameter, and in the 
indexed and non-indexed left ventricular mass. These improvements, both numerically and 
percentage-wise, are reinforced by the ECO-dependent evaluation character. The fact that he 
was the same evaluator before and after the program, and the fact that he has followed the 
patient for ten consecutive years, reinforces the reliability of echocardiographic results. 
Furthermore, it should also be noted that not only did the left ventricular systolic and diastolic 
volumes regress, but also that they adjusted now to the are within normal limits values of these 
variables. 
 
The increased volume of the LA is an important predictor of negative cardiovascular outcomes 
(3, 6). The regression of LA dilation (as seen in Table 2), even an improvement of 4%, for a patient 
with HCM is extremely significant. The decrease in LA is reflected in a reduction in the risk of 
mortality and hospitalization, incidence of atrial fibrillation and stroke, as well as in an increase 
in life expectancy (4). 
 
The mechanisms by which exercise triggers RMR have been described in the literature for some 
time. We highlight here the effect of aerobic intensity cyclic exercise on microRNAs, used in the 
patient's program. Experimental studies with rats demonstrate that physical exercise induces 
the action of microRNAs 21, 132, 155, 146b, 208b, 212 and 214, which are indicated to induce 
RMR and improve cardiac function (14). Although, in this case, cardiac function has undergone 
a slight quantitative improvement (ejection fraction increasing by 5%), it was significant in the 
patient's clinical context. The significant improvement in QL assessed by the Minnesota 
questionnaire, points this out. The evolution of performing ADL as performing domestic 
activities were the points most highlighted by the patient after the SCR program. We cannot 
forget that other factors, such as the decrease in sympathetic hyperactivity (common in these 
patients), improvement in the activity of the renin-angiotensin system, and adaptations in the 
peripheral muscles, may have had as strong an impact on QL as the central improvements (4, 
12). 
 
In HCM cases, some patients may have syncope. At the beginning of treatment, this was one of 
the main complaints of the patient, along with dyspnea on light and moderate exertion, possibly 
caused by a myocardial hypoperfusion and increased oxygen demand characteristic of HCM 
(1). After the five months of SCR, the patient reported that she was no longer presenting with 
episodes of syncope, a condition that contributed to the improvement of her emotional 
perception and, consequently, in QL. 
 
Another point to be highlighted in this case is the work of the multidisciplinary team. The 
benefits mentioned above were due to a personalized physical exercise prescription, 
individualized according to the patient's clinical and biological characteristics. For that, the 
moments of reevaluation and periodization of training carried out by the multidisciplinary 
team, composed of doctors (assistant cardiologist and arrhythmologist) and physiotherapists 
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(specialists in Cardiovascular Rehabilitation) made all the difference in the relevance of the 
results obtained. 
 
Finally, we point out that, as this is a case report, the results presented here must be analyzed 
with caution and impartiality. Despite this, this case report advances something new, the 
possibility of exercise causing reversal of dilation in HCM, and is something that in our 
knowledge has not yet been reported in the literature. We know that a case report is only based 
on the hierarchical scale of scientific evidence. However, it is able to shed light on fields that are 
still little explored in science, the main contribution of this work. In view of the above, this study 
suggests that an individualized and personalized SCR program is an adjuvant treatment capable 
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